Test targeted drugs to help radioactive iodine reach thyroid cancer
Part of Cancer, Hormones & metabolism clinical trials.
This study looks at whether certain cancer “targeted therapy” medicines can make radioactive iodine (RAI) therapy work better for thyroid cancer that has spread to the lungs. It also involves taking special whole-body scans to measure how much radioactive iodine gets taken up by the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have differentiated thyroid cancer confirmed by pathology (biopsy/surgery tissue test)
- Your tumor has a specific target found on lab testing (NTRK, RET, ALK, BRAF, or another targetable change)
- Your CT scan shows lung metastases, such as many small solid nodules or growing discrete nodules
- You are starting an oncogene-specific targeted therapy (or already started) using a plan from a doctor or another approved trial access pathway
- You can get a whole-body thyroid scan without needing sedation or general anesthesia
- You are not pregnant or breastfeeding (because the scan uses radioactive iodine)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a targeted drug called selpercatinib, taken before radioactive iodine therapy, can help treat thyroid cancer in children and young adults who have a specific genetic change (RET fusion or mutation). The drug may make the cancer more sensitive to the radioactive iodine treatment that follows.
This Phase 2 trial tests larotrectinib (a targeted medicine) to help radioactive iodine (RAI) work better in people with differentiated thyroid cancer that has an NTRK gene fusion. It may improve how much thyroid cancer the RAI can reach and shrink.
This trial studies whether giving more radioactive iodine (RAI) can help adults with differentiated thyroid cancer (a type of thyroid cancer) who still have signs of disease in their blood after initial treatment. It is for people who had their thyroid removed and have already had RAI therapy but show persistent or returning biochemical disease (abnormal blood markers) without any visible tumors on scans.
This trial tests if an existing drug (used for other conditions) can help people with advanced thyroid cancer who have run out of treatment options. You'll get a new drug and be monitored to see if it shrinks your cancer or slows it down.
This trial tests whether combining a targeted pill (selpercatinib) with a radioactive iodine dose (I-131) can shrink thyroid cancer that has spread and no longer responds to radioactive iodine. It is for RET fusion–positive (genetically driven) thyroid cancers where the cancer cannot reliably absorb iodine anymore.
This trial tests how much radiation a specialized whole-body PET/CT scan delivers in patients with differentiated thyroid cancer. It may help doctors better plan treatment for cancer that persists, returns, or has spread—especially when radioactive iodine (RAI) may or may not work.
Hear when a new Papillary Thyroid Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.